Table 5.

Demographic and clinical characteristics at baseline between the two treatments (iopamidol versus iodixanol; n = 294)a

CharacteristicIopamidol Group (n = 145)Iodixanol Group (n = 149)Pb
Age (yr; %)
    18 to 6419260.12
    ≥658174
Gender (%)
    male71560.01
    female2944
Baseline eGFR
    severity of CKD (ml/min per 1.73 m2; %)
    <30670.86
    30 to 599493
    eGFR (mean ± SD)50 ± 1151 ± 130.61
Severity of CAD (%)
    no disease14170.12
    1-vessel disease2120
    2-vessel disease3422
    3-vessel disease3141
Congestive heart failure (%)1290.40
Left ventricular ejection fraction (%)
    mean ± SD49 ± 1354 ± 120.01
    <50% (%)34.720.40.02
Hypertension (%)81830.68
Diabetes (%)38400.77
    insulin dependent1517
    non–insulin dependent2323
Duration of diabetes (yr; mean ± SD)11.3 ± 9.012.4 ± 8.30.05
Concomitant medications (%)
    β blockers82.179.20.53
    ACEIs47.649.70.72
    calcium channel blockers42.141.60.94
    diuretics54.555.70.83
  • a ACE, angiotensin-converting enzyme inhibitor; CAD, coronary artery disease.

  • b P value from Fisher exact test or t test, as appropriate.